MTAC Trademark

Trademark Overview

On Tuesday, November 23, 2021, a trademark application was filed for MTAC with the United States Patent and Trademark Office. The USPTO has given the MTAC trademark a serial number of 97139738. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Wednesday, June 19, 2024. This trademark is owned by Avilar Therapeutics, Inc.. The MTAC trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of immunoglogical, neurological, and metabolic diseases mediated by extracellular proteins
mtac

General Information

Serial Number97139738
Word MarkMTAC
Filing DateTuesday, November 23, 2021
Status731 - SECOND EXTENSION - GRANTED
Status DateWednesday, June 19, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of immunoglogical, neurological, and metabolic diseases mediated by extracellular proteins

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 29, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAvilar Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451
Party NameAvilar Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWaltham, MA 02451

Trademark Events

Event DateEvent Description
Friday, November 26, 2021NEW APPLICATION ENTERED
Monday, November 29, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, September 3, 2022ASSIGNED TO EXAMINER
Tuesday, September 6, 2022NON-FINAL ACTION WRITTEN
Tuesday, September 6, 2022NON-FINAL ACTION E-MAILED
Tuesday, September 6, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, March 3, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, March 3, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 3, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 8, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, April 11, 2023PUBLISHED FOR OPPOSITION
Wednesday, March 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 11, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, December 4, 2023SOU TEAS EXTENSION RECEIVED
Monday, December 4, 2023SOU EXTENSION 1 FILED
Monday, December 4, 2023SOU EXTENSION 1 GRANTED
Wednesday, December 6, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 6, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, May 6, 2024SOU EXTENSION 2 FILED
Monday, May 6, 2024SOU TEAS EXTENSION RECEIVED
Monday, May 6, 2024TEAS REQUEST TO DIVIDE RECEIVED
Monday, June 10, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, May 6, 2024TEAS STATEMENT OF USE RECEIVED
Thursday, June 20, 2024SOU EXTENSION 2 GRANTED
Thursday, June 20, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 10, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, June 20, 2024DIVISIONAL REQUEST RECEIVED
Thursday, June 20, 2024DIVISIONAL PROCESSING COMPLETE

Related Keywords

mtac diseases mediated extracellular proteins metabolic neurological preparations treatment immunoglogical pharmaceutical